ArticleJournal of cancer research and clinical oncology2006
Role of glutathione-S-transferase and codon 72 of P53 genotypes in epithelial ovarian cancer patients.
Article in Journal of cancer research and clinical oncology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 7 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Glutathione Transferases Omega-1 and -2 Polymorphisms in Cancer: Drivers or Silent Bystanders?International journal of molecular sciences · 2025Pooled it
- Individual effects ofFrontiers in genetics · 2022Pooled it
- Associations of the glutathione S-transferase P1 Ile105Val genetic polymorphism with gynecological cancer susceptibility: a meta-analysis.Oncotarget · 2017Pooled it
- Genetic polymorphisms in Glutathione S-transferase Omega (GSTO) and cancer risk: a meta-analysis of 20 studies.Scientific reports · 2014Pooled it
- Evaluating the association between p53 codon 72 Arg>pro polymorphism and risk of ovary cancer: a meta-analysis.PloS one · 2014Pooled it
- Association between glutathione S-transferase M 1 null genotype and risk of ovarian cancer: a meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Pooled it
- Meta-analysis shows significant association of the TP53 Arg72Pro with ovarian cancer risk.Molecular biology reports · 2012Pooled it
- The Upregulation of GSTO2 is Associated with Colon Cancer Progression and a Poor Prognosis.Journal of oncology · 2023Article
- Article
- Review
- No association betweenOncotarget · 2017Article
- Association between polymorphisms in xenobiotic detoxification-related genes with prognosis of epithelial ovarian cancer.Medical oncology (Northwood, London, England) · 2016Article
- Improvement of a predictive model in ovarian cancer patients submitted to platinum-based chemotherapy: implications of a GST activity profile.European journal of clinical pharmacology · 2016Article
- Association of GSTO2 (N142D) Genetic Polymorphism and Acute Rejection of Liver.International journal of organ transplantation medicine · 2016Article
- Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy.Journal of experimental & clinical cancer research : CR · 2015Article
- Glutathione S-transferase Omega 2 Genetic Polymorphism and Risk of Hepatic Failure that Lead to Liver Transplantation in Iranian Population.International journal of organ transplantation medicine · 2013Article
- Association between N142D genetic polymorphism of GSTO2 and susceptibility to colorectal cancer.Molecular biology reports · 2011Article
- Translational medicine and reliability of single-nucleotide polymorphism studies: can we believe in SNP reports or not?International journal of medical sciences · 2011Article
- Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients.The pharmacogenomics journal · 2010Article
- Polymorphism of glutathione S-transferase Omega gene: association with risk of childhood acute lymphoblastic leukemia.Journal of cancer research and clinical oncology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeA series of polymorphisms in germ-line DNA have been investigated in an effort to delineate polygenic models of cancer susceptibility and prognosis. As low-penetrance susceptibility genes may combine additively or multiplicatively and contribute to cancer incidence and to the response to chemotherapy, we studied GSTT1, GSTM1, GSTO2, GSTP1 and codon 72 of p53 genotype profiles in ovarian cancer patients.
methodsWe compared 69 ovarian cancer patients with 222 control healthy women paired for ethnic and life-style characteristics. Outcome was evaluated in 29 stage III and IV patients submitted to a platinum-based chemotherapy followed-up for 6-29 months (17 +/- 9 months).
resultsGSTT1, GSTM1, GSTO2 and GSTP1 genes presented a similar genotype distribution, but codon 72 of p53 gene wild-type variant was less frequent in ovarian cancer patients than in controls (chi(2); P = 0.0004).
conclusionsWe were unable to demonstrate any association between the GST genotypes studied and the risk of ovarian cancer but the inheritance of a heterozygous Arg/Pro genotype of p53 increased the risk of ovarian cancer more than 2.5 times (OR = 2.571; 95% CI = 1.453-4.550). There was no association of the studied genes to any clinical or pathological feature of the patients or to their response to chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.